



## **Bicycle Therapeutics to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Conference**

April 6, 2020

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Apr. 6, 2020-- [Bicycle Therapeutics plc](#) (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycles*®) technology, today announced that management will participate in a panel discussion on bispecifics at the Canaccord Genuity Horizons in Oncology Conference on Wednesday, April 8, 2020 at 10:15 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the panel will be accessible in the Investors & Media section of Bicycle's website at [www.bicycletherapeutics.com](http://www.bicycletherapeutics.com). An archived replay of the webcast will be available for 60 days following the presentation date.

### **About Bicycle Therapeutics**

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*®, for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a *Bicycle* Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit [bicycletherapeutics.com](http://bicycletherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200406005076/en/): <https://www.businesswire.com/news/home/20200406005076/en/>

### **Investor and Media Contact:**

Bicycle Therapeutics  
Maren Killackey  
[maren.killackey@bicycletx.com](mailto:maren.killackey@bicycletx.com)  
+1-617-203-8300

Source: Bicycle Therapeutics plc